76 results
Page 2 of 4
8-K
EX-99.1
il0zf
7 Aug 18
BioCryst Reports Second Quarter 2018 Financial Results
7:31am
425
aidnv9kvyboq szsjjkt
21 Jun 18
Business combination disclosure
6:06am
425
9rbbdk
21 Jun 18
Business combination disclosure
12:00am
425
8ttxzv 5q8sagye3
7 Jun 18
Business combination disclosure
8:17am
425
iy91 wgbl8z4xlz
7 Jun 18
Business combination disclosure
8:15am
8-K
EX-99.1
imhz gz8t2s0xen2ea
24 May 18
BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
4:00pm
8-K
td3a6rgy
24 May 18
BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
4:00pm
425
275k0
22 Jan 18
Business combination disclosure
12:00am
8-K
EX-99.1
03z751p
7 Dec 12
Biocryst Pharmaceuticals Announces Focused Corporate Strategy
12:00am
8-K
EX-99.1
g56 o15vkx1af8
30 Nov 12
Termination of a Material Definitive Agreement
12:00am
8-K
EX-99.1
0c3yb2 0zsf8iwta6
8 Nov 12
Biocryst Announces Outcome from the Peramivir Phase 3 Interim Analysis
12:00am
425
EX-99.1
c2kjv7331v
8 Nov 12
Business combination disclosure
12:00am
8-K
EX-99.1
2ci m00wz95v14sh3om0
8 Nov 12
Biocryst Provides Corporate Update and Reports Third Quarter
12:00am